At a Senate Committee on Finance event, senators pressed for stronger prescription drug pricing reforms, touted recent PBM transparency rules, and criticized the administration's engagements with pharmaceutical companies; they discussed Medicare negotiation, reference pricing, and Most-Favored-Nation deals, and took questions from reporters but recorded no votes or formal actions.